This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) to Provide Better Health Equity in North Carolina
by Zacks Equity Research
Centene (CNC) collaborates with Reinvestment Partners to improve the health of North Carolinians.
CNC or HUM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Cigna, Centene and Molina Healthcare
by Zacks Equity Research
Cigna, Centene and Molina Healthcare have been highlighted in this Industry Outlook article.
The Zacks Analyst Blog Highlights AbbVie, Applied Materials, American Express, Centene and Aspen
by Zacks Equity Research
AbbVie, Applied Materials, American Express, Centene and Aspen are included in this Analyst Blog.
Top Stock Reports for AbbVie, Applied Materials & American Express
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Applied Materials, Inc. (AMAT) and American Express Company (AXP).
3 HMO Stocks in Focus Despite High Tech Costs & Nursing Shortage
by Debasmita Chatterjee
Growing customer base and M&A strategies are likely to aid the Medical-HMO industry. However, escalating expenses and a dearth in the availability of medical personnel are concerning. Stocks like CI, CNC and MOH are likely to navigate the industry storms.
5 Low Price-to-Book Stocks for Value Investors
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. General Motors Company (GM), Cemex (CX), Centene (CNC), Enersys (ENS)) and Deutsche Bank Aktiengesellschaft (DB) are some such stocks.
5 Stocks in the S&P 500 ETF to Buy at a Bargain
by Sweta Killa
With the S&P 500 hitting new milestones, valuations are also getting lofty, making investors wary about their investments. For those, we have highlighted five stocks in the S&P 500 ETF that are undervalued, as reflected in their lower P/E ratio than industry peers.
Encompass Health (EHC) Q4 Earnings Beat on Higher Discharges
by Zacks Equity Research
Encompass Health's (EHC) Q4 results gain on improved net patient revenue per discharge and higher net income. Management estimates 2024 adjusted EPS to be $3.77-$4.06.
Tenet Healthcare (THC) Q4 Earnings Beat on Hospital Operations
by Zacks Equity Research
Tenet Healthcare (THC) expects net operating revenues to be between $19.9 billion and $20.3 billion in 2024.
Why Centene (CNC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Company News for Feb 7, 2024
by Zacks Equity Research
Companies in The News Are: ARCB, CNC, ATHM, LIN.
Zacks.com featured highlights Itron, EnerSys, Centene and General Motors
by Zacks Equity Research
Itron, EnerSys, Centene and General Motors have been highlighted in this Screen of The Week article.
Centene (CNC) Q4 Earnings Beat on Membership Growth, View Up
by Zacks Equity Research
Centene (CNC) expects adjusted EPS to be a minimum of $6.70 in 2024, higher than the 2023 figure of $6.68 per share.
4 Low P/CF Stocks to Navigate the Economic Landscape in 2024
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. ITRI, ENS, CNC & GM boast low P/CF ratios.
Centene (CNC) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Highly Ranked Stocks to Watch as Earnings Approach
by Shaun Pruitt
Set to release their quarterly results on Tuesday, February 6, here are several standout stocks that investors will certainly want to pay attention to.
Cigna (CI) Q4 Earnings Beat on Membership Growth, Dividend Up
by Zacks Equity Research
Cigna (CI) expects adjusted revenues to register a minimum growth of 20.3% from the 2023 reported figure.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
Stay Ahead of the Game With Centene (CNC) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Centene (CNC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Molina (MOH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Centene (CNC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CNC vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled
by Zacks Equity Research
Humana (HUM) expects 2024 revenues to increase to around $113 billion.